Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Postphlebitic Syndrome: later-stage trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Postphlebitic Syndrome: 2 US clinical trials tracked, none currently recruiting.

Postphlebitic Syndrome is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 1 of these trials.

Enrollment posture brief

Registry condition postphlebitic-syndrome

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Postphlebitic Syndrome (this)0%
Open-enrollment share among volume-matched conditions near Postphlebitic Syndrome

Postphlebitic Syndrome has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Postphlebitic Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Postphlebitic Syndrome is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Named interventions

Most-linked intervention names on Postphlebitic Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Recombinant tissue plasminogen activator (rt-PA) Drug
1 trials
VeinOPlus Device
1 trials

US sites by state

Facility locations filed on Postphlebitic Syndrome trials. A trial with sites in several states counts in each.

North Carolina 1 trials
Maine 1 trials
Maryland 1 trials
Kentucky 1 trials
Indiana 1 trials
Illinois 1 trials
Iowa 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Postphlebitic Syndrome page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Postphlebitic Syndrome condition card totals 2 registered trials; most-linked intervention Recombinant tissue plasminogen activator (rt-PA); top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.